HDAC9 and medulloblastoma: Of note, the small molecule HDAC inhibitor 4SC-202 displayed high efficacy in both vismodegib-sensitive and SUFU-depleted SMOi-resistant medulloblastoma cells, indicating that inhibition of HDAC activity could bypass the acquired resistance toward SMOi (Gruber et al., 2018).